Hospitals are putting more money behind fewer startups and tying nearly every check to a contract they intend to use themselves. U.S. digital health startups raised $7.4 billion across 244 deals in the first half of 2026, up from $6.4 billion a year earlier, and Rock Health's data reported by Healthcare Dive shows 20 mega-rounds of $100 million or more — from just 19 companies — captured 45% of all dollars while making up only about 8% of deals.
That concentration shows up on the hospital side too. At least 23 U.S. health systems now run dedicated corporate venture arms, according to a Becker's Health IT tracker cited by Global Venturing, and those arms are widening their focus as financial and staffing pressures squeeze hospital budgets elsewhere.
Table of Contents
- Bigger Checks, Fewer Bets
- The New Rule — Invest Only Where You'll Become a Customer
- What This Means for a Startup Raising From a Health System
- Where the Money Is Going
- What a Founder Can Do With This
Bigger Checks, Fewer Bets
The median digital health deal size climbed to $14 million in H1 2026 from $12 million the year before, Rock Health reports. That's a signal hospitals and their co-investors are writing larger checks into fewer companies rather than spreading smaller amounts across a wide set of pilots.
The shift away from scattered proof-of-concept testing shows up in partnership data as well. Galen Growth found digital-health corporate partnerships fell 21% year-on-year to 676 transactions, which the firm interprets as hospitals and corporates moving toward fewer, deeper commitments instead of broad pilot portfolios. For a startup founder, this means a hospital conversation is less likely to end in a small trial and more likely to end in no deal at all, or in a much larger one.
The New Rule — Invest Only Where You'll Become a Customer
The clearest pattern in how hospitals pick startups is that capital now follows commercial intent, not the other way around. Bon Secours Mercy Health's venture arm, Accrete Health Partners, made four new investments in 2025 — Hyro, Hellocare, Trek Health and Definity — and paired every single one with a commercial contract for the health system itself, according to Becker's Hospital Review. The system doesn't fund a company unless it also plans to use that company's product. Definity, a vendor-neutral healthcare workforce platform, shows the mechanics.
In March 2026, Accrete led a $7 million Series A in the company, tying capital from the $13.3-billion-revenue, 47-hospital system directly to a product it intended to deploy internally, per BusinessWire's funding announcement. Accrete's portfolio has since grown to 10 companies touching every operating team at Bon Secours Mercy Health, under chief digital officer Jason Szczuka — a shift Becker's describes as moving from scattered pilot programs toward one centralized, equity-linked investment arm. For a founder courting hospital investors, this means the pitch has to answer a different question than it used to. It's no longer "will this generate returns" alone — it's "will this health system actually deploy what it's funding.".
What This Means for a Startup Raising From a Health System
If a hospital venture arm is on your cap table wishlist, a few practical realities follow from the current pattern:.
- Expect the term sheet to come bundled with a pilot or purchase agreement, not after one. Accrete's model pairs every investment with a commercial contract, so a health system weighing funding will likely ask what deployment looks like before it writes a check.
- Expect competition for a smaller number of slots. With mega-rounds absorbing 45% of all 2026 dollars into 19 companies, capital is concentrating rather than spreading thin, per Rock Health.
- Expect the check size to be larger if you clear the bar. Median deal size rose to $14 million, so hospitals writing in are less likely to treat the investment as a small toe-dip.
- Expect scrutiny on integration across departments, not just one unit. Accrete's 10-company portfolio spans every operating team at its parent system, suggesting health systems increasingly want a startup that can scale across the whole organization, not stay siloed in one pilot.
Where the Money Is Going
Clinical focus still shapes which startups get hospital-adjacent capital. Mental health kept its position as the top-funded clinical indication for the seventh consecutive year in H1 2026, with weight management and obesity close behind, according to Rock Health's H1 2026 report.
A startup building in either category is competing in the most crowded, best-capitalized part of the market — which can mean more investor interest but also more competitors chasing the same hospital partnerships. Individual health-system deals outside Bon Secours' model are also happening — Cedars-Sinai Health Ventures backing Mitera Biosciences, and Healthliant Ventures taking a stake in Ethermed, for instance. But much of the public detail on deals like these comes from investor-database profiles such as PitchBook and Caplight rather than primary press releases, so specific terms should be verified before a founder treats them as confirmed benchmarks for their own negotiations.
What a Founder Can Do With This
The practical takeaway is to treat a hospital venture arm less like a financial investor and more like a future customer who happens to also write equity checks. Before approaching one, a founder should be ready to name the specific department or workflow the health system would deploy the product in, not just describe a market opportunity.
It also pays to ask directly whether the fund has made deployment-linked investments before — Accrete's track record is public specifically because Bon Secours wanted it known. A health system that can't point to a single portfolio company it has actually adopted internally may be a less reliable long-term partner than one, like Accrete, with a consistent pattern of buying what it funds.